Investigational drugs for eating disorders

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.6, Iss.4, 1997-04, pp. : 427-436

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) each occur in about 0.5 - 1.5% of the population in westernised countries, and primarily affect women. At present, a variety of pharmacological treatments are used in addition to psychotherapy, with antidepressants being most the common. Currently available drugs, while helpful, fall far short of desired levels of efficacy. Based on current knowledge about neural mechanisms that regulate feeding behaviour, several classes of compounds are in development to treat eating disorders. These include cholecystokinin (CCK) antagonists, corticotropin-releasing hormone (CRH) antagonists, histamine-3 (H3) receptor antagonists, neuropeptide Y (NPY) antagonists, and a variety of serotonin uptake inhibiting drugs. Based on currently available effective treatments, it seems reasonable that the serotonin uptake inhibiting drugs might hold the greatest likelihood of benefit for these illnesses, but the receptor antagonists in development might provide substantial improvement in response rates.